It has been about a month since the last earnings report for Fate Therapeutics (FATE). Shares have added about 0.5% in that time frame, underperforming the S&P 500. Will the recent positive trend ...

Forbes contributors publish independent expert analyses and insights. David Jagneaux is a writer and analyst, covering MMOs and retro games. When I wrote this headline I paused for a moment because ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

He works in mysterious ways.

Fate Therapeutics, Inc. engages in the development of programmed cellular immunotherapies for cancer and immune disorder. Its pipeline of products includes immuno-ocology candidates and ...